We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit

Delisted

EUCRU was delisted on the 26th of April, 2023.

37 hedge funds and large institutions have $90.4M invested in Eucrates Biomedical Acquisition Corp. Unit in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
37
Holders Change
+37
Holders Change %
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
37
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$853K +$812K +80,000 New
BFM
27
Boothbay Fund Management
New York
$752K +$717K +70,571 New
MS
28
Maven Securities
Jersey
$533K +$508K +50,000 New
TD Asset Management
29
TD Asset Management
Ontario, Canada
$459K +$443K +43,657 New
PAM
30
Panagora Asset Management
Massachusetts
$124K +$121K +11,951 New
HF
31
HRT Financial
New York
$121K +$116K +11,385 New
EAM
32
Exos Asset Management
New York
$112K +$106K +10,486 New
LCM
33
Landscape Capital Management
New Jersey
$107K +$102K +10,000 New
WAM
34
Wolverine Asset Management
Illinois
$35K +$34.1K +3,360 New
UBS Group
35
UBS Group
Switzerland
$19K +$17.8K +1,748 New
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$11K +$10.2K +1,000 New
TRCT
37
Tower Research Capital (TRC)
New York
$1K +$975 +96 New

EUCRU Hedge Fund Activity: Q4 2020 in Review

37 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q4 2020, worth a combined $90.4M.

Buyers outnumbered sellers: 37 funds opened new EUCRU positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $10.2M.

  • 37 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $90.4M of Eucrates Biomedical Acquisition Corp. Unit stock for Q4 2020.
  • 37 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q4 2020 and 0 closed out, a net change of +37 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q4 2020 was Deerfield Management, an estimated $10.2M added.

Based on aggregated 13F filings for Q4 2020.